Patent US4048307A successfully refreshed from Google Patents.
US4048307A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cyclic adenosine monophosphate 8-substituted derivatives
Assignee: Asahi Kasei Corp
•
Filing: 1975-09-24
•
Granted: 1977-09-13
•
Expires: 1995-09-24
Abstract
Abstract Novel cyclic adenosine monophosphate derivatives represented by the following general formula: ##STR1## wherein A stands for --S-- or --NH-- and n is an integer of from 2 to 12, ARE SUPERIOR TO KNOWN CYCLIC ADENOSIENE DERIVATIVES IN BIOLOGICAL AND PHARMACOLOGICAL ACTIVITIES, ESPECIALLY PDE-inhibiting activity and membrane permeability. Accordingly, these derivatives are very effective for remedying and controlling diseases caused by disorder of the intracellular cyclic adenosine monophosphate level, such as asthma and scabies. These derivaives can readily be synthesized by reacting an 8-halogeno cyclic adenosine monophosphate of the following general formula ##STR2## wherein X is a halogen atom such as bromine, with an alkali metal salt of a linear alkylmercaptan having 3 to 13 carbon atoms in the alkyl group or a linear alkylamine having 3 to 13 carbon atoms in the alkyl group.
Inventors
- 👤 Takeshi Yokota
- 👤 Nobuyuki Suzuki
- 👤 Tsuneo Sowa
- 👤 Yasuharu Sasaki
- 👤 Yasutaka Ono
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 06:13
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16; C07H19/20
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
35 words
A cyclic adenosine monophosphate represented by the formula, or its pharmaceutically acceptable non-toxic inorganic or organic salt: ##STR6## wherein A stands for --S-- or --NH-- and n is an integer of from 5 to 12.
Claim 2
Dependent Claim
35 words
A cyclic adenosine monophosphate represented by the formula, or its pharmaceutically acceptable non-toxic inorganic or organic salt: ##STR6## wherein A stands for --S-- or --NH-- and n is an integer of from 5 to 12.
Claim 3
Dependent Claim
13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2, wherein A is --S--.
Claim 4
Dependent Claim
19 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is an integer of from 5 to 8.
Claim 5
Dependent Claim
19 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is an integer of from 9 to 12.
Claim 6
Dependent Claim
13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 1 wherein A is --NH--.
Claim 7
Dependent Claim
18 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is an integer of 5 to 8.
Claim 8
Dependent Claim
18 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is an integer of 9 to 12.
Claim 9
Dependent Claim
13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 5.
Claim 10
Dependent Claim
13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 6.
Claim 11
Dependent Claim
13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 7.
Claim 12
Dependent Claim
13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 8.
Claim 13
Dependent Claim
13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 9.
Claim 14
Dependent Claim
13 words
An 8-alkylmercapto cyclic adenosine monohosphate according to claim 2 wherein n is 10.
Claim 15
Dependent Claim
13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 11.
Claim 16
Dependent Claim
13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 12.
Claim 17
Dependent Claim
13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 5.
Claim 18
Dependent Claim
13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 6.
Claim 19
Dependent Claim
13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 7.
Claim 20
Dependent Claim
13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 8.
Claim 21
Dependent Claim
13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 9.
Claim 22
Dependent Claim
13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 10.
Claim 23
Dependent Claim
13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 11.
Claim 24
Dependent Claim
13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 12.
Claim 25
Dependent Claim
31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 1 and a pharmaceutically acceptable carrier therefor.
Claim 26
Dependent Claim
31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 2 and a pharmaceutically acceptable carrier therefor.
Claim 27
Dependent Claim
31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 3 and a pharmaceutically acceptable carrier therefor.
Claim 28
Dependent Claim
31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 4 and a pharmaceutically acceptable carrier therefor.
Claim 29
Dependent Claim
31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 5 and a pharmaceutically acceptable carrier therefor.
Claim 30
Dependent Claim
31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 6 and a pharmaceutically acceptable carrier therefor.
Claim 31
Dependent Claim
31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 7 and a pharmaceutically acceptable carrier therefor.
Claim 32
Dependent Claim
46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 1.
Claim 33
Dependent Claim
46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 2.
Claim 34
Dependent Claim
46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 3.
Claim 35
Dependent Claim
46 words
A method of treating diseases caused by disorder of the introcellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 4.
Claim 36
Dependent Claim
46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 5.
Claim 37
Dependent Claim
46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 6.
Claim 38
Dependent Claim
46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 7.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-09-12 | 1981-03-14 | 1981-09-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-09-12 | 1985-03-14 | 1985-09-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-09-12 | 1989-03-14 | 1989-09-13 | $7700.00 | Window Closed / Lapsed |